NO951629L - Conjugate vaccine against group B streptococcus - Google Patents

Conjugate vaccine against group B streptococcus

Info

Publication number
NO951629L
NO951629L NO951629A NO951629A NO951629L NO 951629 L NO951629 L NO 951629L NO 951629 A NO951629 A NO 951629A NO 951629 A NO951629 A NO 951629A NO 951629 L NO951629 L NO 951629L
Authority
NO
Norway
Prior art keywords
streptococcus
vaccine against
conjugate vaccine
against group
group
Prior art date
Application number
NO951629A
Other languages
Norwegian (no)
Other versions
NO951629D0 (en
Inventor
James L Michel
Dennis L Kasper
Frederick M Ausubel
Lawrence C Madoff
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Publication of NO951629D0 publication Critical patent/NO951629D0/en
Publication of NO951629L publication Critical patent/NO951629L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO951629A 1992-11-02 1995-04-28 Conjugate vaccine against group B streptococcus NO951629L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02
PCT/US1993/010506 WO1994010317A2 (en) 1992-11-02 1993-11-02 Conjugate vaccine against group b streptococcus

Publications (2)

Publication Number Publication Date
NO951629D0 NO951629D0 (en) 1995-04-28
NO951629L true NO951629L (en) 1995-07-03

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951629A NO951629L (en) 1992-11-02 1995-04-28 Conjugate vaccine against group B streptococcus

Country Status (14)

Country Link
EP (1) EP0669985A1 (en)
JP (1) JPH08505282A (en)
KR (1) KR100349331B1 (en)
AU (1) AU689452B2 (en)
CA (1) CA2146926A1 (en)
FI (1) FI951979A (en)
HU (1) HU220198B (en)
IL (1) IL107458A0 (en)
NO (1) NO951629L (en)
NZ (1) NZ258684A (en)
PL (1) PL177302B1 (en)
RU (1) RU2209247C2 (en)
WO (1) WO1994010317A2 (en)
ZA (1) ZA938171B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
CA2337102A1 (en) * 1998-07-27 2000-02-10 Richard William Falla Le Page Nucleic acids and proteins from group b streptococcus
EA009885B1 (en) * 1998-12-22 2008-04-28 Майкросайенс Лимитед Use of peptide bacteria of group b streptococcus, encoding polynucleotide thereof, vaccine and antibody
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) * 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
JP4102186B2 (en) * 2000-10-13 2008-06-18 アイディー バイオメディカル コーポレイション Group B Streptococcus BVH-A2 and BVH-A3 antigens
JP5102487B2 (en) 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション Polysaccharide staphylococcal surface attachment factor carrier protein conjugate for immunization against nosocomial infections
PT2144924T (en) * 2007-04-16 2016-08-17 Minervax Aps Fusion protein vaccine
KR101734585B1 (en) 2008-08-28 2017-05-11 노파르티스 아게 Cell surface display of polypeptide isoforms by stop codon readthrough
WO2017068112A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
CA3004631A1 (en) 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006267A1 (en) * 1986-04-16 1987-10-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus

Also Published As

Publication number Publication date
EP0669985A1 (en) 1995-09-06
JPH08505282A (en) 1996-06-11
RU2209247C2 (en) 2003-07-27
HU220198B (en) 2001-11-28
CA2146926A1 (en) 1994-05-11
AU5665494A (en) 1994-05-24
PL308555A1 (en) 1995-08-21
WO1994010317A2 (en) 1994-05-11
AU689452B2 (en) 1998-04-02
HUT70981A (en) 1995-11-28
WO1994010317A3 (en) 1994-07-07
FI951979A0 (en) 1995-04-26
FI951979A (en) 1995-06-29
NO951629D0 (en) 1995-04-28
KR950704492A (en) 1995-11-20
NZ258684A (en) 1997-04-24
PL177302B1 (en) 1999-10-29
IL107458A0 (en) 1994-02-27
KR100349331B1 (en) 2003-01-06
ZA938171B (en) 1995-03-07

Similar Documents

Publication Publication Date Title
NO942867L (en) Synthetic haemophilus influenzae conjugate vaccine
NO951629D0 (en) Conjugate vaccine against group B streptococcus
NO921364D0 (en) hybrid
AU6858391A (en) Bundle tie
MX174031B (en) HYBRID INFLATOR
DE69307719T2 (en) HYBRID TRANSMISSION
DE69321907T2 (en) HYBRID COUPLER
FI944052A0 (en) Oral vaccine
DE69309672T2 (en) CLAMP FASTENING DEVICE
FI930631A (en) EN ROTERANDE MOTOR, FOERSEDD MED EN UTBALANSERAD VRIDAXEL
ZA937034B (en) Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
NO970258D0 (en) Double hybrid system
ITVE920048A0 (en) POWERTRAIN COUPLER DEVICE
DE69204500T2 (en) Purified mite allergen.
NO971003D0 (en) Enteral vaccine against vaginal infections
DE69304836D1 (en) Synchronous motor
AU5626998A (en) Conjugate vaccine against group B Streptococcus
NL300165I2 (en) Babesia vaccine.
DE9213623U1 (en) Synchronous motor
SE9602149D0 (en) Conjugate vaccine against streptococcus pneumoniae
NO943251D0 (en) Oral vaccine
DE69326536T2 (en) Antitumor vaccine
DE9309360U1 (en) Traction device
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
ITTO910617A1 (en) EQUIPMENT TO HOLD TWO OVERLAPPING VEHICLES.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application